0.10Open0.10Pre Close0 Volume1 Open Interest15.00Strike Price0.00Turnover229.75%IV121.90%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.0806Delta0.0458Gamma68.05Leverage Ratio-0.0150Theta0.0002Rho5.49Eff Leverage0.0021Vega
Mesoblast Stock Discussion
Mesoblast (MESO) has released an update.
Mesoblast Limited has reported significant progress in its discussions with the FDA, receiving guidance on licensure paths for its innovative therapies, remestemcel-L for pediatric graft versus host disease, and rexlemestrocel-L for end-stage heart failure. The company is poised to resubmit its Biologics License Application for remestemcel-L and seeks an accelerated approval for ...
No comment yet